Accelerating Neurodegenerative Clinical Drug Development with AI
About this webinar
Rapid advancements in artificial intelligence (AI) are revolutionizing central nervous system (CNS) clinical trials in neurodegenerative diseases by improving patient recruitment, optimizing study protocols, analyzing data in greater depth and personalizing treatments. These advances not only enable more efficient and accurate clinical trials, but also speed up the development of new treatments and improve patient outcomes.
AI is revolutionizing the landscape of drug discovery and clinical drug development, particularly within central nervous system (CNS) research for neurodegenerative diseases. The emerging importance of AI in neurodegenerative diseases is underscored by the fact that CNS drug development, in general, has higher failure rates than non-CNS drugs, both preclinically and clinically, indicating that more research is required to ensure safety and efficacy in treatments to slow neurodegeneration.
Read more...
The integration of AI has enhanced the understanding of mechanisms, accelerated novel target identification and fueled advances in drug discovery for neurodegenerative diseases and other CNS disorders. It has helped in generating compounds with unique properties, such as improved specificity or bioavailability. Overall, AI holds immense promise for understanding, diagnosing and managing neurodegenerative diseases, ultimately improving patient outcomes.
Read Less...
Register for this webinar today to gain insights on how AI is playing a crucial role in advancing CNS research related to neurodegenerative clinical drug development.
Who should attend
- Clinical trials
- Clinical operations
- Data management
- Drug development
- Preclinical trials
- Project management
- Regulatory affairs
What you will learn
- The role of AI in dissecting disease pathogenesis
- How AI can improve success rates in neurodegenerative drug discovery
- Methods for accelerating CNS clinical trials with AI, enhancing patient journeys and drug accessibility
Featured Speakers
Anne-Marie Nagy, PhD
Anne-Marie Nagy joined TFS in September 2021 to lead the company’s Internal Medicine and Neurosciences Business Units. Her strategic and operational experience from nearly 25 years at both mid-and large-sized pharmaceutical and clinical research organizations has benefited biotech clients throughout their clinical development journey.
She has extensive experience in neuroscience with broad indications such as those in psychiatry (schizophrenia, MDD, bipolar disorders and anxiety) and neurology, including rare and gene therapy (spasticity, cervical dystonia, rare and non-rare epilepsy, Alzheimer’s, Parkinson’s, multiple sclerosis, neuromuscular disorders, Friedreich ataxia and Rett syndrome).
Read more...
Read Less...
Sara Doan, BSc, DC
Dr. Sara Doan is the Executive Director, Program Strategy and Delivery for Internal Medicine & Neuroscience. She brings a robust 27-year background in global clinical research to her role, with a particular emphasis on psychiatry over the past 12 years. Her expertise spans a broad range of disorders including Alzheimer’s, Parkinson’s, Narcissistic Personality Disorder, Borderline Personality Disorder, Major Depressive Disorder, Post Traumatic Stress Disorder, Bipolar Disorder, Migraine and Anxiety.
Dr. Doan is a Doctor of Chiropractic with a specialization in the central nervous system, having earned her degree from Parker University in Dallas, Texas. She is proficient in both English and Farsi. Dr. Doan demonstrates forward-thinking leadership with a proven track record of success in business operations, coupled with a commitment to excellence in customer management and a strong emphasis on delivering high-level customer service.
Read more...
Recognized for her exceptional ability to cultivate and lead high-performing teams, Dr. Doan emphasizes cohesion, morale, open dialogue and a culture of accountability that fosters innovation and collaboration. She possesses extensive expertise in clinical and project management throughout all stages of clinical trials, with a notable record of successfully leading and managing study teams across fully scoped multicenter studies spanning regions, including North and Latin America, Europe, Asia and Australia.
Read Less...
Partner for this event
TFS HealthScience
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800+ professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology.
Detailed information about TFS and its business offerings can be obtained through www.tfscro.com.